This paper designs a PROTAC that recruits the tissue-specific E3 ligase MAGEA11 to degrade BET proteins in cancer cells, showing selectivity in osteosarcoma and esophageal squamous cell carcinoma lines.

npj Drug Discovery. · Oct 26, 2026Peer-reviewedBiochemistry

EnzCast: Prediction of Patient-Specific Enzymatic Kinetics through Multi-Modal Deep Learning and Isoform-Resolved Bayesian Inference based on Single-Cell Transcriptomics

Xuechen Mu, Yi Yang, Qingyu Wang, Zimin Chen, Bizhe Luo, Zhenyu Huang, Xinyi Lin, Long Xu, Xuan Li, Yinwei Qu, Jun Xiao, Zhihang Wang, Bocheng Shi, Qi Ou, Bowen Yao, , Ying Xu

EnzCast predicts enzymatic kinetics from multi-modal data, and IsoKin infers patient-specific in vivo kinetics, showing improved uncertainty reduction in colorectal cancer.

bioRxiv · Apr 30, 2026 · PreprintBioinformatics

Validating Conditionally Essential Targets: Discovery of the First Orally Effective Biotin Inhibitor against MycobacteriumTuberculosis

Qiang Liu, Joshua B. Wallach, Yahani P. Jayasinghe, Mark R. Sullivan, Julianna Proietto, Suyapa Rodriguez, Stephanie P. Vo, Helena I. Boshoff, Ziyi Jia, Camilla Folvar, Betelhem Tatek, Firat Kaya, Lev Ostrer, Kritee Mehdiratta, Rui Shi, , Courtney C. Aldrich

The paper develops an orally effective biotin inhibitor, C48, against Mycobacterium tuberculosis, demonstrating in vivo efficacy in a low-biotin mouse model.

bioRxiv · Sep 24, 2025 · PreprintMicrobiology